Presented by Dr. Lubna Quosous from the Jordanian Food and Drug Administration, at the Cairo Workshop on assessing governance in sectors, this powerpoint presentation introduces the assessment of transparency and accountability of key functions in the pharmaceutical sector.
The document discusses Chemistry, Manufacturing and Controls (CMC) and its role in pharmaceutical product development and regulatory approval. It provides details on:
- The key functions of CMC including process development, facility inspections, and ensuring compliance.
- CMC content requirements for different application types like NDAs, ANDAs, and INDs.
- How the CMC section evolves over clinical trial phases from laboratory to commercial scale.
- Procedures for developing and submitting post-approval study protocols to regulatory agencies.
2006 PC Revised Guidelines on Non Compliance Last Washington 2012Dr Lendy Spires
The document provides guidance for the Participation Committee in recommending interim measures for participants found to be in serious non-compliance with KPCS requirements. It outlines a roadmap for the committee to investigate non-compliance, which includes raising issues with participants, developing compliance programs with timelines, and considering measures like enhanced monitoring, technical assistance, or suspension of exports and imports as a last resort. It also provides principles like ensuring procedures are consistent with national sovereignty and treating each case uniquely based on its circumstances.
This document provides guidance on conducting pharmacovigilance audits according to international standards. It discusses the legal, technical, and scientific context of pharmacovigilance audits. A risk-based approach to auditing is recommended, focusing on high risk areas like critical processes, quality systems, and areas of noncompliance. Audit findings should be graded based on their criticality and risk level. Corrective actions should address critical and major issues to ensure patient safety and compliance.
PIC/S Guide to GMP PE009-13 - Key changes to Annex 15 - Qualification and val...TGA Australia
The TGA has now legislated version 13 of the PIC/S guide to GMP for medicinal products with a transition period for implementation ending at the end of 2018. Some of the biggest changes in this version were in Annex 15 – Qualification and Validation. This has an impact across all areas in including small to medium sized manufacturers as well as sponsors who need to understand the impact in their supply chain including contract manufacturing and storage and transportation.
This presentation presents how Quality Risk management can be applied in Commissioning & Qualification of Facility , System and Equipments in Pharmaceutical Facilities.
This document outlines quality system requirements for national pharmaceutical inspection services that conduct GMP inspections of manufacturers and wholesale distributors. It specifies that inspection services must establish a quality manual, administrative structure, documentation control, records management, inspection procedures and resources, internal audits, quality improvement processes, and procedures for handling complaints and recalls. The goal is to achieve consistency in inspection standards across national authorities to facilitate mutual recognition and confidence between inspection services.
Japan Medical Device Regulatory Approval ProcessKate Jablonski
Before deciding to sell your device in the Japanese market, it is important to understand how the regulations apply to your device, which steps to take, and what resources are required to complete the process. In this presentation, Ann Marie Boullie, Vice President of Business Development for EMERGO, outlines some of the most complex aspects of the Japanese registration process, including:
JMDN codes: device classification and predicates
Clinical data requirements and PMDA pre-submission meetings
Registration routes (Todokede, Ninsho, Shonin)
QMS (Ordinance 169) requirements
Role of the Marketing Authorization Holder (MAH)
The document discusses Chemistry, Manufacturing and Controls (CMC) and its role in pharmaceutical product development and regulatory approval. It provides details on:
- The key functions of CMC including process development, facility inspections, and ensuring compliance.
- CMC content requirements for different application types like NDAs, ANDAs, and INDs.
- How the CMC section evolves over clinical trial phases from laboratory to commercial scale.
- Procedures for developing and submitting post-approval study protocols to regulatory agencies.
2006 PC Revised Guidelines on Non Compliance Last Washington 2012Dr Lendy Spires
The document provides guidance for the Participation Committee in recommending interim measures for participants found to be in serious non-compliance with KPCS requirements. It outlines a roadmap for the committee to investigate non-compliance, which includes raising issues with participants, developing compliance programs with timelines, and considering measures like enhanced monitoring, technical assistance, or suspension of exports and imports as a last resort. It also provides principles like ensuring procedures are consistent with national sovereignty and treating each case uniquely based on its circumstances.
This document provides guidance on conducting pharmacovigilance audits according to international standards. It discusses the legal, technical, and scientific context of pharmacovigilance audits. A risk-based approach to auditing is recommended, focusing on high risk areas like critical processes, quality systems, and areas of noncompliance. Audit findings should be graded based on their criticality and risk level. Corrective actions should address critical and major issues to ensure patient safety and compliance.
PIC/S Guide to GMP PE009-13 - Key changes to Annex 15 - Qualification and val...TGA Australia
The TGA has now legislated version 13 of the PIC/S guide to GMP for medicinal products with a transition period for implementation ending at the end of 2018. Some of the biggest changes in this version were in Annex 15 – Qualification and Validation. This has an impact across all areas in including small to medium sized manufacturers as well as sponsors who need to understand the impact in their supply chain including contract manufacturing and storage and transportation.
This presentation presents how Quality Risk management can be applied in Commissioning & Qualification of Facility , System and Equipments in Pharmaceutical Facilities.
This document outlines quality system requirements for national pharmaceutical inspection services that conduct GMP inspections of manufacturers and wholesale distributors. It specifies that inspection services must establish a quality manual, administrative structure, documentation control, records management, inspection procedures and resources, internal audits, quality improvement processes, and procedures for handling complaints and recalls. The goal is to achieve consistency in inspection standards across national authorities to facilitate mutual recognition and confidence between inspection services.
Japan Medical Device Regulatory Approval ProcessKate Jablonski
Before deciding to sell your device in the Japanese market, it is important to understand how the regulations apply to your device, which steps to take, and what resources are required to complete the process. In this presentation, Ann Marie Boullie, Vice President of Business Development for EMERGO, outlines some of the most complex aspects of the Japanese registration process, including:
JMDN codes: device classification and predicates
Clinical data requirements and PMDA pre-submission meetings
Registration routes (Todokede, Ninsho, Shonin)
QMS (Ordinance 169) requirements
Role of the Marketing Authorization Holder (MAH)
Pharmacovigilance Audits: Is the USA behind the curve?Medpace
Key takeaways from this presentation are:
•The recognition of the importance of Pharmacovigilance Audits
•To influence the industry to see Pharmacovigilance audits as an effective tool in drug development
Pharmacovigilance "Module I" Pharmacovigilance system & their quality systemMohamed Raouf
This Module contains guidance for the establishment and maintenance of quality assured Pharmacovigilance systems for marketing authorization holders (MAHs) and national medicine authorities (NMAs).
Reference:- Guideline on good pharmacovigilance practices (GVP) version no.3
Speaker: Peter Pekos, Dalton Pharma Services. Part of the MaRS Best Practices Series.This session, led by seasoned industry experts, will explore how to effectively set up your pre-clinical POC studies, address pre-clinical safety requirements and issues, and give you an overview of the manufacturing standards required for Phase I studies
More information: http://www.marsdd.com/Events/Event-Calendar/Best-Practices-Series/ind-05132008.html
The document discusses the inspection of drug distribution channels. It covers the qualifications and attributes of drug inspectors, which include good knowledge of pharmacy laws and regulations, as well as integrity and communication skills. It also describes the organizational aspects of inspectors and different methods of inspection, such as comprehensive, concise, follow-up, and investigative inspections. The objectives of inspecting establishments are to ensure protection of patients, high ethical standards, and compliance with regulations. Special categories of drugs may require a modified inspection procedure.
This document provides guidance on preparing a site master file (SMF) for pharmaceutical manufacturing sites. It outlines the key information that should be included in an SMF, such as descriptions of quality management systems, personnel, facilities, equipment, production, quality control, distribution, and procedures for complaints and recalls. The SMF is intended to provide regulatory authorities with information on GMP compliance during inspections.
An Australian Pharmacovigilance Inspection Program - Pilot ProgramTGA Australia
The Therapeutic Goods Administration (TGA) in Australia is launching a pilot program to inspect companies' pharmacovigilance systems and ensure they are adequately monitoring the safety of medicines available to Australian consumers. Up to 10 pharmaceutical companies will volunteer to participate in the inspections which will review how companies collect, report and monitor adverse drug reactions. The pilot program aims to improve pharmacovigilance practices within companies and help tailor Australia's national inspection program. Feedback from participating companies will be used to analyze whether a full inspection program is suitable and determine its future scope.
Levy GxP QA Auditing Services provides auditing services to ensure compliance with Good Practice standards including GCP, GMP, GLP, GDP, and more. They have a global team of experienced auditors who can audit pharmaceutical companies, clinical trials, laboratories, and more. Their services include regulatory inspections, mock inspections, SOP writing assistance, training, and guidance on compliance with standards.
Good Governance for Medicines in JordanMeTApresents
Jordan has implemented the Good Governance for Medicines program to address issues of corruption in its pharmaceutical sector. It has completed Phases I and II, which included assessing transparency, developing a national framework, and making some initial improvements. Jordan is now in Phase III of implementation. A steering committee and task force have been established to oversee the program. Phase III activities will focus on training, adopting new procedures, and introducing good governance concepts into university curricula to further promote transparency and accountability.
International Regulatory Overview 2009 Rev LinkedlnMdbio
Roger Leclerc presented on international medical device regulatory challenges and overviews. He discussed regulatory bodies and their challenges in Canada, the US, Europe, Australia and Asia. For Health Canada, he outlined strategic objectives like modernization, adequate funding, and improved governance. Key regulatory issues from 2008-2009 included standards recognition, special access programs, significant changes, and sale of unlicensed devices.
Sandra Maddock, RN, BSN, CCRA and President of IMARC Research, Inc. presents on Applying FDA’s Risk-Based Approach in an audio conference on September 11, 2012.
The document discusses Cuba's regulatory bodies for food and drugs - CECMED and MINAL. It describes CECMED's history and roles, which include drug evaluation, quality management, registration, inspections, and clinical trials evaluation. It also covers MINAL's overview and responsibilities in public health policies, services, and procedures. Key aspects of CECMED's drug and biological evaluation, quality management system, registration process, inspections, and the role of the National Control Laboratory are summarized.
PIC/S is a combine term used for the execution of activities of Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme
harmonize, educate, and update aspects relating to Good Manufacturing Practice among member countries
harmonized relation among regulatory authorities and governments
members
history
role
objective and function
guidlines
Presentation Overview of TGA’s involvement in the International Regulatory En...TGA Australia
The document provides an overview of the TGA's involvement in international regulatory activities, including participation in PIC/S (Pharmaceutical Inspection Co-operation Scheme). The TGA works to harmonize GMP standards and inspection procedures through joint inspections with other regulators, information sharing, and involvement in various PIC/S committees and working groups focused on updating guidance and standards. As a member of PIC/S, the TGA contributes to efforts to strengthen global cooperation on GMP inspections and enforcement.
Raj Bhogal, Head of Regulatory Inspections, R&D Quality Takeda on the topic of 'Pharmacovigilance Inspections' at IFAH held at Le Meridien, Dubai on 16th - 18th December, 2019.
The Massachusetts Medical Use of Marijuana Program underwent a multi-step process to select dispensaries to distribute medical marijuana across the state. They received over 200 applications, conducted extensive background checks, had applications reviewed by experts and a selection committee, and the executive director provisionally approved 28 applicants. The approved dispensaries will now begin inspections before receiving final registration to open and distribute medical marijuana to patients. The program will continue to regulate dispensaries and the medical marijuana industry to ensure patient access and public safety.
Good manufacturing practices for complementary medicinesTGA Australia
This presentation provides an overview of GMP clearance application process, the TGA compliance risk framework, major deficiencies and manufacturing quality challenges.
Indian GMP Certification & WHO GMP CertificationVishal Shelke
Indian GMP Certification & WHO GMP Certification by Mr. Vishal Shelke
https://youtube.com/vishalshelke99
https://instagram.com/vishal_stagram
Sub :- Drug Regulatory Affairs
M.Pharm Sem II
Savitribai Phule Pune University
International regulatory cooperation: more important than everTGA Australia
The presentation was given by the TGA at the 2014 ARCS Scientific Congress, and covers the importance and future of international regulatory cooperation
TGA webinar: The Good Manufacturing Practice (GMP) Clearance Framework – an o...TGA Australia
The document provides an overview of Australia's Good Manufacturing Practice (GMP) Clearance Framework. It discusses the legislative basis for manufacturing requirements, the roles and activities of the Manufacturing Quality Branch, and the two pathways for obtaining a GMP Clearance - a desk-based assessment through a Mutual Recognition Agreement or Compliance Verification, or an on-site TGA inspection. It also outlines the history of GMP Clearance, recognized authorities through agreements like MRAs, and the MRA assessment pathway.
This document discusses monitoring governance in REDD programs and initiatives. It outlines a framework for REDD monitoring that includes monitoring both emissions and safeguards, including governance indicators, at both the national reporting level and local implementation level. It reviews several existing governance monitoring initiatives for forests, logging, and REDD. It envisions a common base for governance monitoring across scales and a vision of integrating governance monitoring with overall monitoring, reporting and verification systems to measure change over time in key areas like stakeholder participation, legislation and enforcement, and accountability and transparency.
Pharmacovigilance Audits: Is the USA behind the curve?Medpace
Key takeaways from this presentation are:
•The recognition of the importance of Pharmacovigilance Audits
•To influence the industry to see Pharmacovigilance audits as an effective tool in drug development
Pharmacovigilance "Module I" Pharmacovigilance system & their quality systemMohamed Raouf
This Module contains guidance for the establishment and maintenance of quality assured Pharmacovigilance systems for marketing authorization holders (MAHs) and national medicine authorities (NMAs).
Reference:- Guideline on good pharmacovigilance practices (GVP) version no.3
Speaker: Peter Pekos, Dalton Pharma Services. Part of the MaRS Best Practices Series.This session, led by seasoned industry experts, will explore how to effectively set up your pre-clinical POC studies, address pre-clinical safety requirements and issues, and give you an overview of the manufacturing standards required for Phase I studies
More information: http://www.marsdd.com/Events/Event-Calendar/Best-Practices-Series/ind-05132008.html
The document discusses the inspection of drug distribution channels. It covers the qualifications and attributes of drug inspectors, which include good knowledge of pharmacy laws and regulations, as well as integrity and communication skills. It also describes the organizational aspects of inspectors and different methods of inspection, such as comprehensive, concise, follow-up, and investigative inspections. The objectives of inspecting establishments are to ensure protection of patients, high ethical standards, and compliance with regulations. Special categories of drugs may require a modified inspection procedure.
This document provides guidance on preparing a site master file (SMF) for pharmaceutical manufacturing sites. It outlines the key information that should be included in an SMF, such as descriptions of quality management systems, personnel, facilities, equipment, production, quality control, distribution, and procedures for complaints and recalls. The SMF is intended to provide regulatory authorities with information on GMP compliance during inspections.
An Australian Pharmacovigilance Inspection Program - Pilot ProgramTGA Australia
The Therapeutic Goods Administration (TGA) in Australia is launching a pilot program to inspect companies' pharmacovigilance systems and ensure they are adequately monitoring the safety of medicines available to Australian consumers. Up to 10 pharmaceutical companies will volunteer to participate in the inspections which will review how companies collect, report and monitor adverse drug reactions. The pilot program aims to improve pharmacovigilance practices within companies and help tailor Australia's national inspection program. Feedback from participating companies will be used to analyze whether a full inspection program is suitable and determine its future scope.
Levy GxP QA Auditing Services provides auditing services to ensure compliance with Good Practice standards including GCP, GMP, GLP, GDP, and more. They have a global team of experienced auditors who can audit pharmaceutical companies, clinical trials, laboratories, and more. Their services include regulatory inspections, mock inspections, SOP writing assistance, training, and guidance on compliance with standards.
Good Governance for Medicines in JordanMeTApresents
Jordan has implemented the Good Governance for Medicines program to address issues of corruption in its pharmaceutical sector. It has completed Phases I and II, which included assessing transparency, developing a national framework, and making some initial improvements. Jordan is now in Phase III of implementation. A steering committee and task force have been established to oversee the program. Phase III activities will focus on training, adopting new procedures, and introducing good governance concepts into university curricula to further promote transparency and accountability.
International Regulatory Overview 2009 Rev LinkedlnMdbio
Roger Leclerc presented on international medical device regulatory challenges and overviews. He discussed regulatory bodies and their challenges in Canada, the US, Europe, Australia and Asia. For Health Canada, he outlined strategic objectives like modernization, adequate funding, and improved governance. Key regulatory issues from 2008-2009 included standards recognition, special access programs, significant changes, and sale of unlicensed devices.
Sandra Maddock, RN, BSN, CCRA and President of IMARC Research, Inc. presents on Applying FDA’s Risk-Based Approach in an audio conference on September 11, 2012.
The document discusses Cuba's regulatory bodies for food and drugs - CECMED and MINAL. It describes CECMED's history and roles, which include drug evaluation, quality management, registration, inspections, and clinical trials evaluation. It also covers MINAL's overview and responsibilities in public health policies, services, and procedures. Key aspects of CECMED's drug and biological evaluation, quality management system, registration process, inspections, and the role of the National Control Laboratory are summarized.
PIC/S is a combine term used for the execution of activities of Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme
harmonize, educate, and update aspects relating to Good Manufacturing Practice among member countries
harmonized relation among regulatory authorities and governments
members
history
role
objective and function
guidlines
Presentation Overview of TGA’s involvement in the International Regulatory En...TGA Australia
The document provides an overview of the TGA's involvement in international regulatory activities, including participation in PIC/S (Pharmaceutical Inspection Co-operation Scheme). The TGA works to harmonize GMP standards and inspection procedures through joint inspections with other regulators, information sharing, and involvement in various PIC/S committees and working groups focused on updating guidance and standards. As a member of PIC/S, the TGA contributes to efforts to strengthen global cooperation on GMP inspections and enforcement.
Raj Bhogal, Head of Regulatory Inspections, R&D Quality Takeda on the topic of 'Pharmacovigilance Inspections' at IFAH held at Le Meridien, Dubai on 16th - 18th December, 2019.
The Massachusetts Medical Use of Marijuana Program underwent a multi-step process to select dispensaries to distribute medical marijuana across the state. They received over 200 applications, conducted extensive background checks, had applications reviewed by experts and a selection committee, and the executive director provisionally approved 28 applicants. The approved dispensaries will now begin inspections before receiving final registration to open and distribute medical marijuana to patients. The program will continue to regulate dispensaries and the medical marijuana industry to ensure patient access and public safety.
Good manufacturing practices for complementary medicinesTGA Australia
This presentation provides an overview of GMP clearance application process, the TGA compliance risk framework, major deficiencies and manufacturing quality challenges.
Indian GMP Certification & WHO GMP CertificationVishal Shelke
Indian GMP Certification & WHO GMP Certification by Mr. Vishal Shelke
https://youtube.com/vishalshelke99
https://instagram.com/vishal_stagram
Sub :- Drug Regulatory Affairs
M.Pharm Sem II
Savitribai Phule Pune University
International regulatory cooperation: more important than everTGA Australia
The presentation was given by the TGA at the 2014 ARCS Scientific Congress, and covers the importance and future of international regulatory cooperation
TGA webinar: The Good Manufacturing Practice (GMP) Clearance Framework – an o...TGA Australia
The document provides an overview of Australia's Good Manufacturing Practice (GMP) Clearance Framework. It discusses the legislative basis for manufacturing requirements, the roles and activities of the Manufacturing Quality Branch, and the two pathways for obtaining a GMP Clearance - a desk-based assessment through a Mutual Recognition Agreement or Compliance Verification, or an on-site TGA inspection. It also outlines the history of GMP Clearance, recognized authorities through agreements like MRAs, and the MRA assessment pathway.
This document discusses monitoring governance in REDD programs and initiatives. It outlines a framework for REDD monitoring that includes monitoring both emissions and safeguards, including governance indicators, at both the national reporting level and local implementation level. It reviews several existing governance monitoring initiatives for forests, logging, and REDD. It envisions a common base for governance monitoring across scales and a vision of integrating governance monitoring with overall monitoring, reporting and verification systems to measure change over time in key areas like stakeholder participation, legislation and enforcement, and accountability and transparency.
This presentation is about the basic responsibilities and functions of CDSCO explaining the regulatory body's constitution, comprising of functions of state licensing authority and port offices covering the guidelines for new drug approval process, clinical trails and medical devices. this presentation also give a basic note on SUGAM
Introduction types, Objectives, Management of audit, Responsibilities, Planni...Kunal10679
Audit and regulatory Compliance M.pharmacy Quality Assurance department Sem. 2 Introduction types, Objectives, Management of audit, Responsibilities, Planning Process, Information Gathering, Classifications of Deficiencies of auditing
Insights and Trends from 2021 FDA GCP Inspections.pptxMMS Holdings
The document summarizes insights and trends from the FDA's 2021 GCP inspections. It provides an overview of total inspections, top 483 observations for drugs and devices, and warning letters. Key findings include COVID-19 reducing inspections and alternative tools being used, top drug and device 483 observations relating to documentation and procedures, and most warning letters issued in March and October relating to drugs. It also discusses anticipated changes from the draft ICH E6(R3) guideline and trends for 2022, such as a potential increase in enforcement and focus on data security, quality controls, and corrective actions.
Presentation Risk Based Approach to Inspection FrequencyTGA Australia
This document discusses the TGA's risk-based approach to determining inspection frequency of manufacturing sites. It outlines four levels of compliance risk - from low to intentional non-compliance - and how the TGA responds with levels of help, advice, correction, or enforcement. Inspection frequency is determined based on risk categories of the manufactured products and number/type of deficiencies found, ranging from 36 months for low-risk sites with no deficiencies to compliance management for high-risk sites with major deficiencies. Initial inspections occur within 12 months. Unannounced inspections may be triggered by compliance issues. Regulatory compliance is the minimum standard while market leaders pursue excellence.
Presentation: Medical Devices Single Audit Program (MDSAP) Pilot ProgramTGA Australia
This presentation provides an update on the progress of the Pilot and explores how the results of audits will be used by the participating Regulatory Authorities in support of market authorisation within their jurisdictions.
The document discusses the International Conference on Harmonization (ICH). ICH was established in 1990 to harmonize technical requirements for pharmaceutical registration among countries in Europe, Japan and the United States. It aims to ensure safety, quality and efficacy of drugs while avoiding duplication of testing. Key ICH guidelines cover quality, safety, efficacy and multidisciplinary topics. Stability testing guidelines require evaluating drug products under different storage conditions and timepoints to determine shelf life. The harmonization process has led to over 50 guidelines streamlining pharmaceutical research and development globally.
The document discusses GMP compliance audits. It defines GMP audits as a process to verify that manufacturers follow good manufacturing practices regulations. There are two types of audits - onsite audits, which involve visiting the production site, and desktop audits, which review documentation without a site visit. Audits check various aspects of production including personnel, facilities, equipment, processes, warehousing and more. They help identify issues, ensure proper controls, and improve compliance.
Similar to Good governance for medicines in Jordan (20)
Este proyecto busca evaluar el estado de la democracia en Chile a través de un proceso participativo e inclusivo. Se desarrollaron indicadores en tres áreas: partidos políticos, sistema electoral y régimen político. Para 2011, se validarán estos indicadores, se realizará una encuesta nacional y foros regionales, y se redactará un informe final sobre la democracia chilena al bicentenario del país.
With the help of this power point presentation, Noha El-Mikawy, UNDP Governance Practice leader for the Arab States Region, summarized main messages from the first day of the workshop in Cairo on assessing governance in sectors (June 2009) and discussed the process of conducting a country-led assessment.
In this powerpoint presentation Kevin Brown, an expert in public management reform, presents the UNDP publication: Users' Guide for Measuring Public Administration Performance. The presentation was held at the Cairo Workshop on Assessing Governance in Sectors and Application of Governance Evidence in Policy Making, June 2009.
In this power point presentation, Eitan Felner, consultant for the UNDP, at the Cairo Workshop on Assessing Governance in Sectors, looks at synergies between Human Rights and empirically-based socio-eocnomic analysis.
This powerpoint presentation held by Lara El-Jazairi at the Centre On Housing Rights and Evictions, Right to Water Programme, provides an overview of rights based indicators and how they can be used by governments and other actors to monitor progress in achieving the right to water and sanitation.
This tool prepared by the Centre on Housing Rights and Evictions provides a framework that is gender sensitive and pro-poor for assessing water governance.
Inclusive process, rigourous methodology and policy uptake are the key issues raised in this power point presentation by Paul van Hoof, senior advisor on local governance with IDASA, at the Cairo workshop on assessing governance in sectors, June 2009.
Presented at the Workshop on Assessing Governance in Sectors, Governance Assessment Methods and Applications of Governance Data in Policy-Making (June 2009) by Mustafa Khawaja from the Palestinian Central Bureau of Statistics, this powerpoint presentation showcases governance statistics in Palestine.
This power point presentation, from Mohamed Ramzy at the WHO Regional Office for the Eastern Mediterranean at the Cairo Workshop on Assessing Governance in Sectors, uses the WHO framework on Good Governance for Medicines as a starting point to discuss the application of governance data in policy-making.
With the help of this powerpoint presentation, Ken Mease, discusses the advantages of various types of data sources and collection methods, including archival and secondary data, survey data, quantitative and qualitative approaches and data, and finally de jure and de facto information. The presentation was held at the Workshop on Governance Assessment Methods and Applications of Governance Data in Policy-Making (June 2009)
Prepared by Ken Mease, this powerpoint presentation held at the Workshop on Governance Assessment Methods and Applications of Governance Data in Policy-Making (June 2009), looks at indicators more closely, and discusses definitions of indicators, macro and micro levels for constructing indicators, different advantages of de jure and de facto indicators, triangulation, indexes versus scales, objective indicators such as reported behaviours and events, perception based indicators such as opinions, and proxy indicators.
With the help of this powerpoint presentation, at the Workshop on Governance Assessment Methods and Applications of Governance Data in Policy-Making (June 2009), Ken Mease argued that governance assessments can be 1) a reporting tool that can track and communicate progress towards goals and/or outcomes; 2) a policy tool that can guide evidence-based planning and action to address issues identified as important by citizens and in existing political commitments, and finally 3) a tool that can strengthen democracy by engaging stakeholders through informed discussions.
Participatory Corruption Appraisals (PCAs) were used in Indonesia to understand how corruption affects the poor. The methodology involved 3 steps: 1) focus group discussions with poor communities to identify corrupt practices and their effects; 2) case interviews with individuals to learn their stories; 3) reporting back findings to spur discussion and follow-up actions. PCAs captured how corruption imposed financial, social, and human capital costs on the poor. It eroded trust in communities and exacerbated their exclusion from public services. Publishing the poor's stories and establishing anti-corruption networks in their communities aimed to amplify their voices and spur corrective actions.
The document outlines the basic steps of communication planning:
1) Decision-making to organize a management plan for implementing the strategy
2) Setting the policy agenda by identifying targeted changes, aims, and objectives
3) Setting the communication agenda to determine how to influence change through audience analysis and messaging
4) Developing an action plan identifying activities to engage decision-makers and audiences
It also discusses tailoring communication for different audiences, using media strategically, and providing examples of national communication strategies developed in Yemen and Macedonia.
1. Good Governance for Medicines
in Jordan
Dr. Lubna Qusous
Rational Drug Use Department
Jordan Food and Drug Administration
2. JORDAN
• Jordan is a low middle – income country
• Population in millions: 5,894,960
• 10.4 % of the Jordanian GDP is spent on health with one
third of this spent on medicinal drugs.
• One quarter of the drug expenditure is spent in the public
sector with the remaining three quarter spent in the private
sector.
• Medicines expenditure growth 17% per annum compared to
GDP growth of 3.3%.
3. Good Governance for Medicines
programme: a model process
Clearance
MOH
PHASE I PHASE II PHASE III
National Development Implementation
transparency national GGM national GGM
assessment framework programme
Assessment GGM framework GGM Strategic
report officially Plan of Action
adopted
4. PHASE I PHASE II PHASE III
Assessment of transparency and
accountability October - November /2007
• Assesses vulnerability to corruption of systems in
place
• Looks at key functions of the pharmaceutical
sector systems
National
assessment
Regulation: registration, inspection, promotion
Supply: selection, procurement, distribution
•Elements evaluated:
- Country's regulations and official documents
Assessment
report - Written procedures and decision-making
processes
- Committees, criteria for membership and
conflict of interest policy
- Appeals mechanisms and other monitoring
systems
5. General Findings
Area Total Number of Score on 10 Degree of
indicators Key point scale vulnerability to
Informants corruption
Registration 16 10 7.52 marginally
Promotion 12 10 1.88 extremely
Inspection 11 10 5.79 moderately
Selection 12 10 7.71 marginally
Procurement 15 11 8.59 minimally
Distribution 15 10 8.41 minimally
Total 66 61 6.65 marginally
6. General Findings
Area Strength Weakness
Registration - Documented and standardized. - No written guidelines on COI
- Fair access to information - For some committees: No clear criteria
- Formal appeals process for selecting the members & no written
- Specialized TC guidelines for the committees decision-
making process
Promotion Pre-approval of promotional and - Lack of legal coverage
advertising materials for public is - No sanctions for breaching the law
officially required - Pre-approval of promotional and
advertising materials are not officially
required.
Inspection - Comprehensive provision in the - No written guidelines COI
medicines legislation - No clear criteria for selection and
- Written guidelines on recruitment of inspectors.
classification of GMP - No written procedures to prevent
- Written SOPs for inspectors on regulatory capture
how to conduct inspection - No appeal system for companies.
7. General Findings
Area Strength Weakness
Selection JRDL is available in a printed format- - No written guidelines on COI
and in the website of the JFDA - Membership is not time-limited.
Clear guidelines for addition-deletion- - The criteria for selecting drugs are not
for medicines from the list publicly available
- 17 selection committees is appointed to - Only includes experts from medicine and
give technical advice on the revision and pharmacy field.
updating of the RDL
Procurement transparent procedures for procurement- - No written guidelines on COI
of pharmaceutical products - Not all medicine procured are from a national
Formal appeals process - rational drug list.
- Clear and specific criteria for tender
committee membership.
Distribution Medicines can be identified by imprints- - There is no effective security management to
on containers and external packaging. oversee storage and distribution
There is systematic and orderly shelving- - There is no programme exist for monitoring
of products in warehouses. and evaluating the performance of the medicine
The warehouses are subjected to internal distribution system.
and external auditing.
- A computerized system
8. Areas of Improvement
Registration - Conflict of interest policy
- Committee composition & TOR
Promotion - Complete provisions to cover all
Activities related to drug promotion
Inspection - Conflict of interest policy
- Clear criteria for selection of inspectors
Selection - Conflict of interest policy
- Selection criteria for members
Procurement - Conflict of interest policy
- Audit results publicly available
9. General Recommendations
• Revision of the laws and procedures
• There should be written guidelines on COI
• Publish all available regulations, guidelines, SOPs
concerning each area to the public.
• Develop and adopt a framework for good governance
in the public pharmaceutical sector
• Develop expertise-train Jordanian officials and staff on
good governance and ethical practices in drug
management
10. PHASE I PHASE II PHASE III Assessment of
transparency in Jordan
• The results of the assessment and
recommendations were disseminated to the
stakeholders through a national workshop in
February/2008
• Assessment report was published and
disseminated in January 2009
• Improvements in the procedures of the
pharmaceutical sector took place
11. Activities to achieve phase II plan
• Conducting a National Multi-Stakeholders workshop
to disseminate results of the transparency assessment;
• Nominating and selecting National GGM Team
Steering Committee and the task force (TOR);
• Committing to meet on weekly basis and the TF
members prepared the GGM Framework over their
regular duties
• training and building capacity of a national core team
• Finalization and getting consensus and approvals for
the GGM Framework
• Set a plan for Phase III, socialization and
dissemination of the Framework.
12. GGM Steering Committee
• Members are high level policy makers
• Responsible for the overall management, adoption and
evaluation of the GGM programme
• Ensure implementation of recommendations made in
assessment report
• Ensure that the national Framework for Good Governance in
the public pharmaceutical sector is officially adopted
• Ensure the establishment of policies and procedures for the
control of reprehensible acts
• Ensure the establishment of a whistle-blowing mechanism
• Ensures the establishment and implementation of a GGM
programme (phase III)
13. GGM Task Force
The GGM Task Force main tasks include:
1. Manage the national consultations process necessary to:
a. Share the results of the national assessments of transparency
and vulnerability to corruption in the public pharmaceutical
sector and
b. Develop and implement the national GGM framework that
approved by the steering committee
2. Follow-up and act upon the recommendations made in the
national assessments report and by the steering committee.
3. Coordinate the development, adoption, and socializing the
national ethical framework and the code of conduct
14. Jordan GGM Framework Partnership
• Ministry of Health.
• Ministry of Public Sector Development.
• Jordan Food & Drug Administration.
• Anti Corruption Commission.
• Royal Medical Services.
• High Health Council.
• Joint Procurement Department.
• Jordan University Hospital.
• World Health Organization.
15. Jordan GGM Framework
Sequence of the document
1. Introduction to GGM Framework
1. GGM Framework purpose, guiding principles and
requirements
2. Scope and mandate to improve transparency and
accountability
3. Mechanisms and approaches (desk review, national GGM
team dynamics, authority gained by SC high level
representation)
4. Output and expected impact (deliverables: document,
competent team, better access to quality affordable
medicines, more efficiency in the public sector resources
and to have a good model in the region)
16. Jordan GGM Framework
Sequence of the document
2. Governance and AC
• definition, requirements, local and global initiatives International, regional,
bilateral and UN agreements and treaties in addition to AC work in Jordan
to date:
– Law of litigation No 16 of 1960
– Jordan Constitution in 1952
– The Inspection and Control Bureau in 1992.
– The Economic criminals law in 1993.
– Anti Corruption Department in the Intelligence department in 1996.
– Higher Committee for transparency and accountability in 2002.
– The national committee against corruption , nepotism & favoritism to
implement Jordan First Initiative in 2002.
– The Anti-corruption Commission in 2006
– The Ombudsmen Bureau in 2008 (harmful actions and inactions)
17. Jordan GGM Framework
Sequence of the document
3. Good Governance in the Ph. Sector
• medicine chain cycle and management functions
– R&D
– Clinical research
– Production, registration and pricing
– Licensing and certification to individuals and institutions
– Inspection
– Selection, procurement & distribution
– Prescription and dispensing practices
– Pharmacovigilance
– Promotion
• expected types of corruption; conflict of interest, bribery, promotion,
tenders and distribution.
• impact of corruption on health systems and health outcomes, directions and
actions for future protection
• Directions for strengthening and protection
18. Jordan GGM Framework
Sequence of the document
4. Integrity system in Jordan and in the Ph. Sector.
• National integrity system components (leadership, restructuring, rule of
law, public awareness and AC bodies)
• GGM Framework in the Ph. Sector approach in Jordan
– Elements of GGMF
1. Ethical framework of moral values & ethical principles
– Justice/fairness
– Truth
– Service to common good
– trusteeship
2. Code of conduct developed in Jordan in 2002
1. Duties & responsibilities of the Public servant
2. Respect and equity consideration in providing services
3. Confidentiality and disclosure
4. Acceptance of gifts, privileges and other benefits
5. Conflict of interest
19. Jordan GGM Framework
Sequence of the document
5. Socialization of the programme
Raising awareness, dissemination of TA results, encourage critical
thinking and discussions, situation analysis and setting targets and
promote individual responsibility and moral values practices
Transformation of dysfunctional mental models and supporting the
culture for good practices and moral values (awards ceremonies and
incentive linked to performance and moral practices
6. Promotion of Moral Leadership
1. basic elements of the conceptual framework
2. Capabilities grouped in categories that facilitate personal
transformation in a healthy relationships and team work in addition to
the capabilities needed for social transformation
3. Activities to be taken
20. Jordan GGM Framework
Sequence of the document
7. Enforcement of existing Anti-corruption laws
- UN Treaty for Anti corruption in 2004
- Related legislations in Jordan
- AC Law No 62 in 2006
- JFDA Law No 41 in 2008
- Public health Law No 47 in 2008
- Medicine and Pharmacy law No 80 in 2001
- Criminal Law
- Pharmacy licensing law No 43 in 1972
- Bureau of Audit Law
- Administration inspection court law in 1992
- Ombudsmen law No. 11 year 2008
- General procurement law No 32 in 1993 and its amendments
- Civil Service Bylaws No 30 year 2007
- Joint Procurement Law No 91 year 2002
Strengthening institutions and departments working on Anti-corruption in Jordan
21. Jordan GGM Framework
Sequence of the document
• Whistle Blowing
– Strict criteria for WB
– Clear mechanisms
– Protection & security for reporter
• Sanctions on reprehensible acts
– Internal sanctions by the government entity
– Sanctions by the AC agencies and legislative courts
22. Jordan GGM Framework
Sequence of the document
8. Improving management system
Criteria for selecting committee members
GGM Framework implementation
Policies and mechanisms to ensure implementation
of SC recommendations
Monitoring plan for enforcement of GGM SC
resolutions
23. Jordan GGM Framework
Sequence of the document
9. Inter-institutional Collaboration
Audit department in MOH,JFDA
Ministry of Public Sector Development
AC Commission
Audit Bureau
Ombudsmen Bureau
10. Management & evaluation of GGM
programme
full time staff
Setting targets and indicators
24. Jordan GGM Framework
Sequence of the document
• Role of Media and Civil Society
– Empowerment, involvement and building their capacity to act as a
watch dog and pressure groups
– Involvement in raising awareness and education of the public
• Role of private sector
– Corrupted –corruptor responsibility (AC bodies)
• Political will and commitment
– Regular monitoring –advocacy events
– Building local capacity to institutionalize the moral values
– Partnership between government and civil society
– Financial support to implement and sustain GGM framework.
25. Progress
• In January 2009 a Phase III training workshop was
held for the first time in Jordan. It focused on anti-
corruption & pharmaceutical sector legal frameworks,
implementation of the recommendations included in
the transparency assessment (Phase I) & moral
leadership capabilities.
• Among 26 countries globally including 5 countries in
EMR, 10 countries are in phase I, 11 countries in
phase II and 5 in phase III including Jordan.
• Jordan recently finalized the national GGM
framework, and is the 1st EMR country to enter the
implementation phase ( phase III). .
26. PHASE I PHASE II
Implementation of
PHASE III
National GGM Programme
• Strengthening systems by increasing
transparency and accountability
• Promoting awareness (general public &
health professionals)
Implementation – Dissemination of information
national GGM (newsletter, website, etc.)
programme
– Social marketing (radio, TV jingles,
posters, etc.)
GGM Strategic – Critical thinking and discussions
Plan of Action
(seminars, conferences)
• Building capacity (managers and public
policy makers)
– Technical training programme
– Leadership training programme
27. Suggested Activities in Jordan for
Phase III
• Training of the national GGM team, briefing sessions
for government officials, production of advocacy
materials
• Implementing recommended changes in related laws
& procedures to increase transparency
• Adoption of a code of conduct for civil servants
working in the pharmaceutical sector
• Development of a COI guidelines
• Introducing the GGM concept into university
curricula.